Cardlytics Q1 Revenue Plunges 39%, Missing Analyst Expectations
CDLX sits 28% above its 52-week low of $0.664.
Summary
Cardlytics reported a significant 39% year-over-year decline in Q1 revenue to $34.32 million, falling short of analyst expectations of $37.20 million. This specific negative detail regarding revenue provides crucial context following an earlier 8-K filing summary that broadly indicated "strong Q1 financial results" and "exceeding guidance." While the company did beat adjusted EPS estimates and completed a divestiture to strengthen its balance sheet, the substantial revenue contraction, attributed partly to a banking partner mix shift, is a major concern for investors. Traders will be closely watching Q2 guidance, which projects revenue between $35.0 million and $40.0 million, to assess the company's ability to stabilize its top-line performance.
At the time of this announcement, CDLX was trading at $0.85 on NASDAQ in the Technology sector, with a market capitalization of approximately $43.1M. The 52-week trading range was $0.66 to $3.28. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.